牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ D - Notice of Exempt Offering of Securities Filed: 2019-05-31 AccNo: 0001213900-19-009894 Size: 12 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-05-30 AccNo: 0000919574-19-003892 Size: 110 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13D - General statement of acquisition of beneficial ownership Filed: 2019-05-30 AccNo: 0001178913-19-001619 Size: 102 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-29 AccNo: 0001213900-19-009682 Size: 84 KB 网页链接
$灿菲特生物制药(CANF)$ F-1/A [Amend] - Registration statement for certain foreign private issuers Filed: 2019-05-28 AccNo: 0001213900-19-009654 Size: 765 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-24 AccNo: 0001213900-19-009534 Size: 10 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-23 AccNo: 0001213900-19-009450 Size: 26 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-22 AccNo: 0001213900-19-009378 Size: 412 KB 网页链接
$灿菲特生物制药(CANF)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-05-22 AccNo: 0001213900-19-009380 Size: 587 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-05-22 AccNo: 0001535610-19-000087 Size: 13 KB 网页链接